Has William Skinner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $345,766 in general payments to William Skinner, MD across 1,471 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Skinner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Skinner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Skinner, MD

Cardiovascular Disease · Lexington, KYNPI 1447337860

Payments from drug & device makers

$345,766in general payments, 2019–2025

Across 1,471 payments — averaging $235.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$117K
Johnson & Johnson$92K
Esperion Therapeutics, Inc.$67K
Novartis$28K
Lexicon Pharmaceuticals, Inc.$27K
Medtronic$4K
plus $12K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	146	$116,831
Johnson & Johnson(2 entities)	335	$91,943
Esperion Therapeutics, Inc.	134	$66,885
Novartis	154	$27,583
Lexicon Pharmaceuticals, Inc.	50	$26,825
Medtronic(2 entities)	36	$3,626
Boston Scientific	49	$1,150
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	37	$1,007
Merck	46	$812
Actelion Pharmaceuticals US, Inc.	40	$780
AstraZeneca	38	$734
Pfizer	54	$678
Sanofi-aventis U.S. LLC	34	$654
Abbott	13	$511
United Therapeutics Corporation	26	$470
Amarin Pharma, Inc.	35	$452
Novo Nordisk	19	$372
Boehringer Ingelheim	24	$367
Bayer	23	$358
Lundbeck LLC	21	$294
Chiesi USA, Inc.	15	$234
E.r. Squibb & Sons, L.L.C.	15	$220
Regeneron Healthcare Solutions, Inc.	13	$210
Cook Medical LLC	12	$194
Penumbra, Inc.	3	$191
Philips North America LLC	2	$185
Janssen Scientific Affairs, LLC	2	$183
Azurity Pharmaceuticals, Inc.	10	$177
Atricure, Inc.	4	$159
Kowa Pharmaceuticals America, Inc.	10	$156
Terumo Medical Corporation	7	$146
Lilly USA, LLC	7	$135
Gilead	10	$126
Cvrx, Inc.	1	$119
Kestra Medical Technology Services, Inc.	1	$118
Alnylam Pharmaceuticals Inc.	5	$108
Arbor Pharmaceuticals, Inc.	6	$103
Daxor Corporation	1	$61
Amryt Pharma Holdings Ltd	3	$53
Takeda Pharmaceuticals U.S.A., Inc.	2	$52
Bridgebio Pharma, Inc.	2	$46
Kiniksa Pharmaceuticals, Ltd.	3	$44
Portola Pharmaceuticals, LLC	2	$43
Sanofi	1	$32
Acist Medical Systems, Inc.	2	$31
Astellas Pharma US Inc	2	$31
Cardiva Medical, Inc.	1	$31
AbbVie	2	$28
Aegerion Pharmaceuticals, Inc.	2	$28
Cardiovascular Systems Inc.	2	$26
Irhythm Technologies, Inc.	1	$24
Angiodynamics, Inc.	1	$23
Eisai Inc.	1	$20
Kiniksa Pharmaceuticals International, PLC	1	$20
Kyowa Kirin, Inc.	1	$20
Sun Pharmaceutical Industries Inc.	1	$17
Shockwave Medical, Inc	1	$17
Teva Pharmaceuticals USA, Inc.	1	$13
Verge Medical, Inc.	1	$13

How this compares

$345,766 in reported general payments places this provider in the 95th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky →

Medicare billing

Part B allowed, 2024

$665,719

Medicare patients

1,538

Services billed

7,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Lexington

John KotterLexington$241K
Suresh SharmaLexington$204K
John GurleyLexington$171K
David MoliternoLexington$115K
David BoothLexington$115K
Andrew LeventhalLexington$80K
Vincent SorrellLexington$49K
Emma BirksLexington$27K
Steve LeungLexington$24K
James CragerLexington$12K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →